Amgen Effort To Reclaim Procrit Rights From J&J Moving To Trial Phase

Amgen will receive a trial in its arbitration claim seeking to terminate Johnson & Johnson's license to sell Procrit in the U.S., but appears to have a difficult burden to meet before the arbitration panel.